LIXT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Valuation Metrics

The current forward P/E ratio for Lixte Biotechnology Holdings Inc (LIXT.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Lixte Biotechnology Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LIXT News & Events

Events Timeline

No data

News

8.5

2025-12-22Globenewswire

Lixte Biotechnology Secures $4.3 Million Financing for Cancer Treatment Development

8.5

2025-12-18Newsfilter

Lixte Biotechnology Secures $4.3 Million in Registered Direct Offering

8.5

2025-11-25Newsfilter

LIXTE Acquires Liora Technologies to Advance Cancer Treatment Standards

People Also Watch

Frequently Asked Questions

What is Lixte Biotechnology Holdings Inc (LIXT) stock price today?

The current price of LIXT is 3.65 USD — it has decreased -2.67 % in the last trading day.

What is Lixte Biotechnology Holdings Inc (LIXT)'s business?

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.

What is the price predicton of LIXT Stock?

Wall Street analysts forecast LIXT stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LIXT is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Lixte Biotechnology Holdings Inc (LIXT)'s revenue for the last quarter?

Lixte Biotechnology Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Lixte Biotechnology Holdings Inc (LIXT)'s earnings per share (EPS) for the last quarter?

Lixte Biotechnology Holdings Inc. EPS for the last quarter amounts to -0.33 USD, decreased -25.00 % YoY.

What changes have occurred in the market's expectations for Lixte Biotechnology Holdings Inc (LIXT)'s fundamentals?

The market is revising No Change the revenue expectations for LIXT for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -23.48%.

How many employees does Lixte Biotechnology Holdings Inc (LIXT). have?

Lixte Biotechnology Holdings Inc (LIXT) has 2 emplpoyees as of January 10 2026.

What is Lixte Biotechnology Holdings Inc (LIXT) market cap?

Today LIXT has the market capitalization of 31.77M USD.